Aurora Spine’s Second Patent Related to DEXA Technology™ Patient-Matched Implant Technology Issued by the United States Patent Office
05 Februar 2024 - 1:30PM
Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:
ASG), a designer and manufacturer of innovative medical devices
that improve spinal surgery outcomes, today announced the issuance
of its second United States Patent No: 11,850,162 entitled “Body
Density Scan Result-Matched Orthopedic Implants and Methods of Use”
for The World’s First DEXA Technology™ Patient-Matched Implant
Technology.
Aurora Spine’s first-of-its kind DEXA
Technology™ is designed to match a patient’s bone density, promote
bone in-growth while maintaining the biomechanical structure and
bone support. This patent will be utilized to create implants that
match the patient’s specific bone density based on a DEXA
Scan/T-score allowing for the best bone fusion treatment and most
favorable outcome based on that patient’s bone density.
Aurora Spine’s DEXA Technology™ is part of the
company's advanced portfolio representing the future of Spinal and
Orthopedic implants. Following fundamental principles of patent
focused innovation, DEXA Technology™ was logically created and
patented to combine the essential design benefits of conventional
machining and additive implant manufacturing.
In 2022, the company launched its first DEXA
Technology based product, the DEXA-C interbody spacer line for
anterior cervical fusion which is now well accepted by physicians
as one of the most significant implant products to fight decreasing
bone density due to aging. The same year, Aurora’s proprietary DEXA
Technology received the prestigious 2022 Best New Spine Technology
Award.
"Aurora Spine’s first in the world and first to
market DEXA Technology™ based implant provides surgeons with the
choice in selecting the matching density implant for their
patient," said Trent Northcutt, President & CEO of Aurora
Spine. "Aurora’s second patent for bone quality-matching implants
strengthens the Company’s intellectual property portfolio
significantly. Our proprietary DEXA Technology represents our
continued commitment to delivering best-in-class implants that
enable our surgeon partners to overcome common osteoporosis
challenges faced in traditional procedures.”
Laszlo Garamszegi, Chief Technology Officer of
Aurora Spine, added “Traditionally, medical devices for spinal
procedures are designed as ‘one size fits all’ and assumes that
every patient’s bone density is the same. The proprietary
engineering behind our DEXA Technology™ is advancing the science of
implant technology, and ultimately helping improve patient fusion
rates and overall clinical outcomes. These patents will allow us to
create DEXA implants for use anywhere in the human body where bone
fixation is needed providing patients with previously non-existing
new treatment possibilities”.
About Aurora Spine
Aurora Spine is focused on bringing new
solutions to the spinal implant market through a series of
innovative, minimally invasive, regenerative spinal implant
technologies.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-Looking Statements
This news release contains forward-looking
information that involves substantial known and unknown risks and
uncertainties, most of which are beyond the control of Aurora
Spine, including, without limitation, those listed under "Risk
Factors" and "Cautionary Statement Regarding Forward-Looking
Information" in Aurora Spine's final prospectus (collectively,
"forward-looking information"). Forward-looking information in this
news release includes information concerning the proposed use and
success of the company’s products in surgical procedures. Aurora
Spine cautions investors of Aurora Spine's securities about
important factors that could cause Aurora Spine's actual results to
differ materially from those projected in any forward-looking
statements included in this news release. Any statements that
express, or involve discussions as to, expectations, beliefs,
plans, objectives, assumptions or future events or performance are
not historical facts and may be forward-looking and may involve
estimates, assumptions and uncertainties which could cause actual
results or outcomes to differ unilaterally from those expressed in
such forward-looking statements. No assurance can be given that the
expectations set out herein will prove to be correct and,
accordingly, prospective investors should not place undue reliance
on these forward-looking statements. These statements speak only as
of the date of this press release and Aurora Spine does not assume
any obligation to update or revise them to reflect new events or
circumstances.
Contact:
Aurora Spine Corporation
Trent NorthcuttPresident and Chief Executive
Officer(760) 424-2004
Chad ClouseChief Financial Officer(760)
424-2004www.aurora-spine.com
Aurora Spine (TSXV:ASG)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Aurora Spine (TSXV:ASG)
Historical Stock Chart
Von Okt 2023 bis Okt 2024